The Fondazione Policlinico Universitario Agostino Gemelli IRCCS leads Pilot 4 of the COMFORTage project, an interventional study expected to commence in January 2025, involving 200 participants with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). This study focuses on the primary and secondary prevention of cognitive decline by evaluating the impact of lifestyle interventions—including dietary habits, physical activity, cognitive stimulation, and prevention of cardiovascular and metabolic risk factors—on cognition and biomarkers. Over a 36-month period, the research aims to assess how these interventions affect cognitive performance and quality of life, stratified by clinical, genetic, connectivity, and biomarker profiles, with data collected continuously throughout the study duration.
Title: Integration of biomarkers, genetic and clinical risk factor
Partner: FPG
Type: Interventional
Target: Individuals with SCD (Subjective Cognitive Decline) and MCI (Mild Cognitive Impairment).
Focus: 1) Personalized prevention of cognitive decline through the combined use of: clinical and genetic biomarkers, metabolic and cardiovascular risk factors, and modifiable lifestyle factors (nutrition, physical exercise, cognitive training); 2) risk stratification and individual response to interventions.
Type of prevention targeted:Primary prevention (aims to prevent the onset of dementia in individuals with risk factors); secondary prevention (early intervention in individuals with SCD or MCI to delay progression to dementia
Objective: Evaluate the differential impact of a 2-year intervention on cognitive performance and quality of life in individuals with SCD and MCI, stratified according to clinical, genetic, connectivity, and biomarker profiles
